The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring

Syeda Maheen Batool; Anudeep Yekula; Prerna Khanna; Tiffaney Hsia; Austin S. Gamblin; Emil Ekanayake; Ana K. Escobedo; Dong Gil You; Cesar M. Castro; Hyungsoon Im; Tugba Kilic; Michelle Andrea Garlin; Johan Skog; Daniela M. Dinulescu; Jonathan Dudley; Nishant Agrawal; Jordan Cheng; Fereidoun Abtin; Denise R. Aberle; David Chia; David Elashoff; Tristan Grognan; Kostyantyn Krysan; Scott S. Oh; Charles Strom; Michael Tu; Fang Wei; Rena R. Xian; Steven J. Skates; David Y. Zhang; Thi Trinh; Mark Watson; Rebecca Aft; Siddarth Rawal; Ashutosh Agarwal; Susan B. Kesmodel; Changhuei Yang; Cheng Shen; Fred H. Hochberg; David T.W. Wong; Abhijit A. Patel; Nickolas Papadopoulos; Chetan Bettegowda; Richard J. Cote; Sudhir Srivastava; Hakho Lee; Bob S. Carter; Leonora Balaj

doi:10.1016/j.xcrm.2023.101198

The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring

Syeda Maheen Batool, Anudeep Yekula, Prerna Khanna, Tiffaney Hsia, Austin S. Gamblin, Emil Ekanayake, Ana K. Escobedo, Dong Gil You, Cesar M. Castro, Hyungsoon Im, Tugba Kilic, Michelle Andrea Garlin, Johan Skog, Daniela M. Dinulescu, Jonathan Dudley, Nishant Agrawal, Jordan Cheng, Fereidoun Abtin, Denise R. Aberle, David ChiaDavid Elashoff, Tristan Grognan, Kostyantyn Krysan, Scott S. Oh, Charles Strom, Michael Tu, Fang Wei, Rena R. Xian, Steven J. Skates, David Y. Zhang, Thi Trinh, Mark Watson, Rebecca Aft, Siddarth Rawal, Ashutosh Agarwal, Susan B. Kesmodel, Changhuei Yang, Cheng Shen, Fred H. Hochberg, David T.W. Wong, Abhijit A. Patel, Nickolas Papadopoulos, Chetan Bettegowda, Richard J. Cote, Sudhir Srivastava, Hakho Lee, Bob S. Carter, Leonora Balaj

Research output: Contribution to journal › Review article › peer-review

70 Scopus citations

Abstract

The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for cancer and other diseases. Liquid biopsy allows minimally invasive molecular characterization of cancers for diagnosis, patient stratification to therapy, and longitudinal monitoring. Liquid biopsy strategies include detection and monitoring of circulating tumor cells, cell-free DNA, and extracellular vesicles. In this review, we address the current understanding and the role of existing liquid-biopsy-based modalities in cancer diagnostics and monitoring. We specifically focus on the technical and clinical challenges associated with liquid biopsy and biomarker development being addressed by the Liquid Biopsy Consortium, established through the National Cancer Institute. The Liquid Biopsy Consortium has developed new methods/assays and validated existing methods/technologies to capture and characterize tumor-derived circulating cargo, as well as addressed existing challenges and provided recommendations for advancing biomarker assays.

Original language	English
Article number	101198
Journal	Cell Reports Medicine
Volume	4
Issue number	10
DOIs	https://doi.org/10.1016/j.xcrm.2023.101198
State	Published - Oct 17 2023

Access to Document

10.1016/j.xcrm.2023.101198

Cite this

Batool, S. M., Yekula, A., Khanna, P., Hsia, T., Gamblin, A. S., Ekanayake, E., Escobedo, A. K., You, D. G., Castro, C. M., Im, H., Kilic, T., Garlin, M. A., Skog, J., Dinulescu, D. M., Dudley, J., Agrawal, N., Cheng, J., Abtin, F., Aberle, D. R., ... Balaj, L. (2023). The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring. Cell Reports Medicine, 4(10), Article 101198. https://doi.org/10.1016/j.xcrm.2023.101198

@article{653b0c392aca4cd7b3456eefda7c888f,

title = "The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring",

abstract = "The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for cancer and other diseases. Liquid biopsy allows minimally invasive molecular characterization of cancers for diagnosis, patient stratification to therapy, and longitudinal monitoring. Liquid biopsy strategies include detection and monitoring of circulating tumor cells, cell-free DNA, and extracellular vesicles. In this review, we address the current understanding and the role of existing liquid-biopsy-based modalities in cancer diagnostics and monitoring. We specifically focus on the technical and clinical challenges associated with liquid biopsy and biomarker development being addressed by the Liquid Biopsy Consortium, established through the National Cancer Institute. The Liquid Biopsy Consortium has developed new methods/assays and validated existing methods/technologies to capture and characterize tumor-derived circulating cargo, as well as addressed existing challenges and provided recommendations for advancing biomarker assays.",

author = "Batool, {Syeda Maheen} and Anudeep Yekula and Prerna Khanna and Tiffaney Hsia and Gamblin, {Austin S.} and Emil Ekanayake and Escobedo, {Ana K.} and You, {Dong Gil} and Castro, {Cesar M.} and Hyungsoon Im and Tugba Kilic and Garlin, {Michelle Andrea} and Johan Skog and Dinulescu, {Daniela M.} and Jonathan Dudley and Nishant Agrawal and Jordan Cheng and Fereidoun Abtin and Aberle, {Denise R.} and David Chia and David Elashoff and Tristan Grognan and Kostyantyn Krysan and Oh, {Scott S.} and Charles Strom and Michael Tu and Fang Wei and Xian, {Rena R.} and Skates, {Steven J.} and Zhang, {David Y.} and Thi Trinh and Mark Watson and Rebecca Aft and Siddarth Rawal and Ashutosh Agarwal and Kesmodel, {Susan B.} and Changhuei Yang and Cheng Shen and Hochberg, {Fred H.} and Wong, {David T.W.} and Patel, {Abhijit A.} and Nickolas Papadopoulos and Chetan Bettegowda and Cote, {Richard J.} and Sudhir Srivastava and Hakho Lee and Carter, {Bob S.} and Leonora Balaj",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = oct,

day = "17",

doi = "10.1016/j.xcrm.2023.101198",

language = "English",

volume = "4",

journal = "Cell Reports Medicine",

issn = "2666-3791",

number = "10",

}

Batool, SM, Yekula, A, Khanna, P, Hsia, T, Gamblin, AS, Ekanayake, E, Escobedo, AK, You, DG, Castro, CM, Im, H, Kilic, T, Garlin, MA, Skog, J, Dinulescu, DM, Dudley, J, Agrawal, N, Cheng, J, Abtin, F, Aberle, DR, Chia, D, Elashoff, D, Grognan, T, Krysan, K, Oh, SS, Strom, C, Tu, M, Wei, F, Xian, RR, Skates, SJ, Zhang, DY, Trinh, T, Watson, M , Aft, R, Rawal, S, Agarwal, A, Kesmodel, SB, Yang, C, Shen, C, Hochberg, FH, Wong, DTW, Patel, AA, Papadopoulos, N, Bettegowda, C, Cote, RJ, Srivastava, S, Lee, H, Carter, BS & Balaj, L 2023, 'The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring', Cell Reports Medicine, vol. 4, no. 10, 101198. https://doi.org/10.1016/j.xcrm.2023.101198

TY - JOUR

T1 - The Liquid Biopsy Consortium

T2 - Challenges and opportunities for early cancer detection and monitoring

AU - Batool, Syeda Maheen

AU - Yekula, Anudeep

AU - Khanna, Prerna

AU - Hsia, Tiffaney

AU - Gamblin, Austin S.

AU - Ekanayake, Emil

AU - Escobedo, Ana K.

AU - You, Dong Gil

AU - Castro, Cesar M.

AU - Im, Hyungsoon

AU - Kilic, Tugba

AU - Garlin, Michelle Andrea

AU - Skog, Johan

AU - Dinulescu, Daniela M.

AU - Dudley, Jonathan

AU - Agrawal, Nishant

AU - Cheng, Jordan

AU - Abtin, Fereidoun

AU - Aberle, Denise R.

AU - Chia, David

AU - Elashoff, David

AU - Grognan, Tristan

AU - Krysan, Kostyantyn

AU - Oh, Scott S.

AU - Strom, Charles

AU - Tu, Michael

AU - Wei, Fang

AU - Xian, Rena R.

AU - Skates, Steven J.

AU - Zhang, David Y.

AU - Trinh, Thi

AU - Watson, Mark

AU - Aft, Rebecca

AU - Rawal, Siddarth

AU - Agarwal, Ashutosh

AU - Kesmodel, Susan B.

AU - Yang, Changhuei

AU - Shen, Cheng

AU - Hochberg, Fred H.

AU - Wong, David T.W.

AU - Patel, Abhijit A.

AU - Papadopoulos, Nickolas

AU - Bettegowda, Chetan

AU - Cote, Richard J.

AU - Srivastava, Sudhir

AU - Lee, Hakho

AU - Carter, Bob S.

AU - Balaj, Leonora

PY - 2023/10/17

Y1 - 2023/10/17

N2 - The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for cancer and other diseases. Liquid biopsy allows minimally invasive molecular characterization of cancers for diagnosis, patient stratification to therapy, and longitudinal monitoring. Liquid biopsy strategies include detection and monitoring of circulating tumor cells, cell-free DNA, and extracellular vesicles. In this review, we address the current understanding and the role of existing liquid-biopsy-based modalities in cancer diagnostics and monitoring. We specifically focus on the technical and clinical challenges associated with liquid biopsy and biomarker development being addressed by the Liquid Biopsy Consortium, established through the National Cancer Institute. The Liquid Biopsy Consortium has developed new methods/assays and validated existing methods/technologies to capture and characterize tumor-derived circulating cargo, as well as addressed existing challenges and provided recommendations for advancing biomarker assays.

AB - The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for cancer and other diseases. Liquid biopsy allows minimally invasive molecular characterization of cancers for diagnosis, patient stratification to therapy, and longitudinal monitoring. Liquid biopsy strategies include detection and monitoring of circulating tumor cells, cell-free DNA, and extracellular vesicles. In this review, we address the current understanding and the role of existing liquid-biopsy-based modalities in cancer diagnostics and monitoring. We specifically focus on the technical and clinical challenges associated with liquid biopsy and biomarker development being addressed by the Liquid Biopsy Consortium, established through the National Cancer Institute. The Liquid Biopsy Consortium has developed new methods/assays and validated existing methods/technologies to capture and characterize tumor-derived circulating cargo, as well as addressed existing challenges and provided recommendations for advancing biomarker assays.

UR - http://www.scopus.com/inward/record.url?scp=85173183195&partnerID=8YFLogxK

U2 - 10.1016/j.xcrm.2023.101198

DO - 10.1016/j.xcrm.2023.101198

M3 - Review article

C2 - 37716353

AN - SCOPUS:85173183195

SN - 2666-3791

VL - 4

JO - Cell Reports Medicine

JF - Cell Reports Medicine

IS - 10

M1 - 101198

ER -

The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring

Abstract

Access to Document

Other files and links

Fingerprint

Cite this